Four Essential Journals from the AACR

Priority reading for over 50 years – cited more than any other journal in its field

CANCER RESEARCH
Vol. 56, 1996 (24 issues)
ISSN 0008-5472
Editor-in-Chief:
Carlo M. Croce, M.D.
• State-of-the-art laboratory and clinical investigations
• Advances in Brief
• Selected review articles
• Proceedings of the American Association for Cancer Research: annual issue of research abstracts

CANCER RESEARCH
Vol. 56, 1996
ISSN 0008-5472
Editor-in-Chief:
Carlo M. Croce, M.D.

• Original in vitro and in vivo studies of the molecular biology of cancer, including normal and abnormal cellular processes
• Research Capsules
• Viewpoints

INDIVIDUAL NONMEMBERS:
$460; Outside U.S.: $550
INSTITUTIONS:
$595*; Outside U.S.: $725*
*Includes a subscription to Cancer Research. Available as a combined subscription only.

CELL GROWTH & DIFFERENTIATION
Vol. 7, 1996 (12 issues)
ISSN 1044-9523
Editor-in-Chief:
George F. Vande Woude, Ph.D.

• Original research on the molecular biology of cancer
• State-of-the-art laboratory and clinical investigations
• Advances in Brief
• Selected review articles
• Proceedings of the American Association for Cancer Research: annual issue of research abstracts

INDIVIDUAL NONMEMBERS:
$95
INSTITUTIONS:
$245; Outside U.S.: $285

AN UP-TO-THE-MINUTE JOURNAL SPANNING THREE VITAL FIELDS
CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION
Vol. 5, 1996 (12 issues)
ISSN 1055-9965
Editor-in-Chief:
Pelayo Correa, M.D.

• Original research on causes and prevention of cancer in humans
• Invited editorials
• Selected review articles
• Short communications
• Meeting reports

INDIVIDUAL NONMEMBERS:
$85
INSTITUTIONS:
$215; Outside U.S.: $255

AN EXCITING NEW FORUM FOR CLINICAL AND TRANSLATIONAL CANCER RESEARCH
CLINICAL CANCER RESEARCH
Vol. 2, 1996 (12 issues)
ISSN 1078-0432
Editor-in-Chief:
John Mendelsohn, M.D.

• Research articles
• Advances in Brief
• Minireviews
• Controversies in Clinical Cancer Research

INDIVIDUAL NONMEMBERS:
$95
INSTITUTIONS:
$595*; Outside U.S.: $725*
*Includes a subscription to Cancer Research. Available as a combined subscription only.

ORDER TODAY!
American Association for Cancer Research
c/o FULCO, Inc.
P.O. Box 3000
Denville, NJ 07834
1-800-875-2997 or (201) 627-2427
FAX: (201) 627-5872

MEMBERS, AMERICAN ASSOCIATION FOR CANCER RESEARCH:
For member rates, contact the AACR at: (215) 440-9300
FAX (215) 440-9313.

Institutions: Purchase all four journals and save 15% off the total subscription price, excluding postage outside U.S.
Canada: Add 7% GST to all orders. MD: Add state sales tax.
40th Anniversary Symposium  
Department of Experimental Therapeutics, Roswell Park Cancer Institute  
October 3-4, 1996

The program of this Symposium, which commemorates the 40th anniversary of the inauguration of the Department of Experimental Therapeutics at Roswell Park Cancer Institute, consists of lectures from former graduate students of the Department. The Symposium is dedicated to the memory of the department senior staff members who passed away during the 40 years of its existence: Drs. W. Werkheiser (1972), C. Dave (1978), W. Korytnyk (1985), H. Schwartz (1990), G. Grindey (1993), C. Coutsogeorgopoulos (1995).

**Molecular Approaches to Cancer Therapeutics**  
Honorary Chair: Thomas B. Tomasi  
Chairs: Charles A. Nichol and Enrico Mihich  
Program Committee: Drs. E. Mihich, R. Baker, A. Bloch, B. Dolnick, M. Ip, C. Porter, Y. Rustum

**October 3, 1996**

**Session I: Oncogenes and Transcription, Co-Chairs: F. Rosen and A. Bloch**
- B. Feuerstein  
  Genetic instability and progression in Glial tumors
- F. Rauscher III  
  Designing transcriptional repressors which inhibit malignant cell growth

**Session II: Oncogenes and Transcription, Co-Chairs: F. Rosen and M. Ip**
- R. Beckmann  
  Investigations towards identifying the functions of BRCA1
- R. Craig  
  MCL-1 and the emergence of a BCL-2 gene family
- M. Morin  
  Discovery and development of efficacious and safer therapies by selective inhibition of tumor cell signaling
- J. Rosen  
  Regulation of growth and terminal differentiation in the mammary gland and breast cancer

**Session III: Antimetabolites, Co-Chairs: Y-C. Cheng and Y. Rustum**
- R. Moran  
  The human folypoly-γ-glutamate synthetase gene and its role in the selectivity of folate antimetabolites
- S. Berger  
  Therapeutic approaches for colon cancer utilizing thymidylate synthase as a target

**Session IV: New Leads, Co-Chairs: Y-C. Cheng and B. Dolnick**
- P. Vertino  
  DNA methyltransferase and the establishment of aberrant CpG island methylation in tumorigenesis: New targets for chemotherapeutic intervention
- M. Faletto  
  Unique intracellular activation of 1592U89, a carbocyclic purine nucleoside analog with potent anti-HIV activity
- C. Nichol  
  Evening Keynote Address: The Development of the Department of Experimental Therapeutics

**October 4, 1996**

**Session V: New Leads, Co-Chairs: M. Hakala and C. Porter**
- R. Casero  
  Spermidine/spermine N1-acetyltransferase Induction: A Potential Mechanism of Differential Drug Sensitivity
- J. Laskin  
  The 40th anniversary of 5-fluorouracil

**Session VI: New Leads, Co-Chairs: M. Hakala and E. Mihich**
- S. Cohen  
  Non-lymphoid solid tumor cell lines can mimic the phenotype of lymphocytes
- T. Carey  
  Genetic analysis of field cancerization and tumor progression in squamous cell carcinoma: New paradigms to consider in therapeutic planning
- S. Caradonna  
  dUTP hydrolysis and uracil-DNA repair as potential determinants in cancer chemotherapy

Registration deadline: September 15, 1996. For further information please contact Dr. E. Mihich, Roswell Park Cancer Institute, Buffalo, NY 14263, Tel: 716-845-5860; Fax: 716-845-8857.
CELL SIGNALING AND CANCER TREATMENT

An American Association for Cancer Research Special Conference
in Collaboration with
Austrian Cancer Society, British Association for Cancer Research,
German Cancer Society and the Austrian Biochemical Society

February 23-28, 1997
Interalpen-Hotel Tyrol
Telfs-Buchen, Austria

CONFERENCE CHAIRPERSONS
Hans H. Grunicke / Innsbruck, Austria
Garth Powis / Tucson, USA
Paul Workman / Macclesfield, England

PROGRAM COMMITTEE

Sara A. Courtneidge / Redwood City, USA
Sylvie Gisselbrecht / Paris, France
Bernd Groner / Freiburg, Germany
Adrian L. Harris / Oxford, England
Peter A. Herrlich / Karlsruhe, Germany
Peter Hilgard / Frankfurt, Germany
Alex Matter / Basel, Switzerland
Frank P. McCormick / Richmond, USA
Laurent Meijer / Roscoff, France
Michael J. Morin / Groton, USA
Axel Ullrich / Munich, Germany

Keynote Address
Paul Workman / Macclesfield, England

Growth Factor Antagonists and Growth
Factor Receptor Blockers
Enrique Rozengurt / London, England
Nancy E. Hynes / Basel, Switzerland
Bernd Groner / Freiburg, Germany
Nicholas Lydon / Basel, Switzerland

Receptor and Post Receptor Signaling:
Mechanisms and Targets in Cancer
Chemotherapy
Sara A. Courtneidge / Redwood City, USA
Frank P. McCormick / Richmond, USA
Nicholas K. Tonks / Cold Spring Harbor, USA
Garth Powis / Tucson, USA
Ulf R. Rapp / Würzburg, Germany
Alan K. Hall / London, England
Axel Ullrich / Munich, Germany

Cell Cycle and Cancer
Laurent Meijer / Roscoff, France
Christian Brechot / Paris, France
Rolf Müller / Marburg, Germany
J. Wade Harper / Houston, USA

Cytokine Signaling
Sylvie Gisselbrecht / Paris, France
Atsushi Miyayama / Tokyo, Japan
Ian M. Kerr / London, England
Gennaro Ciliberto / Rome, Italy

Programmed Cell Death: Role in Oncogenesis
and Tumor Therapy
Gerard I. Evan / London, England
Caroline Dive / Manchester, England
Douglas R. Green / La Jolla, USA
Donald W. Nicholson / Pointe-Claire-Dorval, Quebec, Canada

Invasion and Metastasis
Max M. Burger / Basel, Switzerland
Louis F. Reichardt / San Francisco, USA
John G. Collard / Amsterdam, The Netherlands
Helmut Ponta / Karlsruhe, Germany

Angiogenesis
Adrian L. Harris / Oxford, England
Kari K. Alitalo / Helsinki, Finland
Isaiah J. Fidler / Houston, USA

Applicants are encouraged to submit abstracts
for poster presentation.

Application deadline: November 1, 1996

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: aacr@aol.com
AMERICAN ASSOCIATION FOR CANCER RESEARCH  
SCIENTIFIC CONFERENCES

OCTOBER 2-6, 1996  
**Novel Approaches in Blood and Marrow Transplantation**  
Second Annual Meeting of the American Society for Blood and Marrow Transplantation  
Chairpersons: O. Michael Colvin, Durham, NC; Bruce R. Blazar, Minneapolis, MN  
Hotel Del Coronado, San Diego, CA

OCTOBER 6-9, 1996  
**Carcinogenesis from Environmental Pollution: Assessment of Human Risks and Strategies for Prevention**  
Joint Meeting with International Agency for Research on Cancer  
Chairpersons: Frederica Perera, New York, NY; Paul Kleihues, Lyon, France  
Hotel Gellért, Budapest, Hungary

OCTOBER 19-23, 1996  
**Programmed Cell Death**  
Chairpersons: Stanley J. Korsmeyer, St. Louis, MO; Shigekazu Nagata, Osaka, Japan; Andrew Wyllie, Edinburgh, Scotland  
The Sagamore, Bolton Landing (Lake George), NY

JANUARY 10-14, 1997  
**Basic and Clinical Aspects of Lymphoma**  
Joint Meeting with the American Society of Clinical Oncology  
Chairpersons: Joseph R. Bertino, New York, NY; James O. Armitage, Omaha, NE  
Stouffer Renaissance Esmeralda Resort, Indian Wells (Palm Springs), CA

JANUARY 17-21, 1997  
**Disrupted Transcription Factors in Cancer**  
Chairpersons: Peter K. Vogt, La Jolla, CA; Frank J. Rauscher III, Philadelphia, PA  
Hotel Del Coronado, San Diego, CA

FEBRUARY 13-16, 1997  
**Growth Factors, Signaling, and Cancer**  
Joint Meeting with Lorne Cancer Conference  
Chairpersons: Antony Burgess, Parkville, Victoria, Australia; Robert J. Coffey, Nashville, TN; Ashley R. Dunn, Parkville, Victoria, Australia; Webster K. Cavenee, La Jolla, CA  
Erskine House, Lorne, Victoria, Australia

FEBRUARY 23-28, 1997  
**Cell Signaling and Cancer Treatment**  
In Collaboration with British Association for Cancer Research, Austrian Cancer Society, German Cancer Society, and Austrian Biochemical Society  
Chairpersons: Hans H. Grunicke, Innsbruck, Austria; Garth Powis, Tucson, AZ; Paul Workman, Macclesfield, England  
Interalpen-Hotel Tyrol, Telfs-Buchen, Austria

MARCH 7-12, 1997  
**Basic and Clinical Aspects of Breast Cancer**  
Chairpersons: J. Carl Barrett, Research Triangle Park, NC; Karen S.H. Antman, New York, NY; Mary-Claire King, Seattle, WA  
Keystone Resort, Keystone, CO

APRIL 12-16, 1997  
**88th Annual Meeting**  
Chairperson: Frederick P. Li, Boston, MA  
Co-Chairpersons: Clara Derber Bloomfield, Buffalo, NY; Stephen H. Friend, Seattle, WA  
San Diego Convention Center, San Diego, CA  
Abstract Deadline: November 12, 1996

JUNE 7-12, 1997  
**Cancer of the Central Nervous System**  
Conference with Neurosurgery Joint Section on Tumors  
Chairpersons: Peter McL. Black, Boston, MA; Webster K. Cavenee, La Jolla, CA  
Loew's Coronado Bay Resort, San Diego, CA

AACR members will receive brochures on the above conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research  
Public Ledger Building, Suite 816  
150 South Independence Mall West  
Philadelphia, PA 19106-3483  
215-440-9300 • 215-440-9313 (FAX)  
E-Mail: aacr@aol.com

For regular updates to this list visit the AACR's World Wide Web site, http://www.aacr.org
Postdoctoral Fellowships in Molecular Cancer Biology

Postdoctoral positions open September 1, 1996 with a newly established research group at the M.D. Anderson Cancer Center for talented Ph.D. and/or M.D. scientists in the following disciplines: APOPTOSIS. Current studies include: (1) mechanisms by which apoptotic responses to chemotherapy are modulated by growth factor-mediated signal transduction pathways and by regulators of cell cycle traversal; (2) mechanisms of apoptosis induced by therapeutic agents including the role(s) of anti- and pro-apoptotic gene products.

GROWTH FACTORS. Ongoing investigations include: (1) novel mechanisms of action of anti-EGF receptor monoclonal antibodies; (2) mechanisms of heregulin/NDF action; (3) regulatory interactions between receptor tyrosine kinases and estrogen receptors in breast carcinoma cells.

Cell Cycle. Research focuses on: (1) regulation of cyclin dependent kinase inhibitors (2) regulation of nuclear matrix proteins.

Experience in molecular biology, biochemistry, and signal transduction is desirable. For immediate consideration, please send curriculum vitae and names of three references to one of the three Principal Investigators in the group: Drs. John Mendelsohn, Rakesh Kumar, Zhen Fan, Laboratory of Cell Growth Regulation, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 91, Houston, Texas 77030. An equal opportunity employer.

---

THE SURGERY BRANCH, NATIONAL CANCER INSTITUTE, NIH, IS SEEKING PATIENTS FOR ONGOING CLINICAL TREATMENT PROGRAMS.

PATIENTS WITH THE FOLLOWING MALIGNANCIES ARE BEING TREATED UNDER COMBINED MODALITY OR INNOVATIVE IMMUNOTHERAPY PROGRAMS:

- METASTATIC MELANOMA AND KIDNEY CANCER
- STAGE II OR LOCALLY ADVANCED BREAST CANCER
- METASTATIC COLORECTAL CANCER TO THE LIVER
- LOCOREGIONAL GASTRIC OR PANCREATIC CANCER
- MESOTHELIOMA, PULMONARY METASTASES, STAGE IIIA, B LUNG CANCER OR ESOPHAGEAL CANCER
- LOCALIZED SOFT TISSUE SARCOMAS
- PERITONEAL CARCINOMATOSIS

CARE FOR ALL PATIENTS IS PROVIDED AT THE CLINICAL CENTER, NIH, BETHESDA, MARYLAND.

FOR MORE INFORMATION ON CANCER PROGRAMS, PLEASE CALL (301) 496-1533

A PUBLIC SERVICE ANNOUNCEMENT COURTESY OF THIS PUBLICATION
Henry T. Lynch (cover) is the recipient of the 19th Annual Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research for his work in establishing the hereditary basis of certain gastrointestinal, breast, and ovarian cancers.

Dr. Lynch is Professor and Chairman of Preventive Medicine and Public Health and Professor of Medicine at Creighton University School of Medicine in Omaha, NE. He is also Director of the Creighton Cancer Center and manages a database of thousands of family pedigrees tracing hereditary cancers. In addition, he established Creighton's Hereditary Cancer Prevention Clinic, which offers information and services related to all hereditary cancers.

During the 1960s, when cancer was thought to be triggered almost solely by environmental causes, Dr. Lynch identified a previously unrecognized form of colon cancer, hereditary non-polyposis colon cancer (HNPCC), now known as Lynch Syndrome, and he demonstrated Mendelian patterns of inheritance for this disease in hundreds of extended families worldwide. During the same period, he also demonstrated Mendelian in-

heritance patterns for certain breast and ovarian cancers, later termed Hereditary Breast/Ovarian Cancer Syndrome, which he subsequently helped link to the BRCA1 and BRCA2 breast cancer genes. With the recent discovery by other researchers of the genes that cause Lynch Syndrome, it has become possible to predict with near 90% accuracy the risk of disease in patients with direct germ line mutations. With early detection, Lynch Syndrome and other colon cancers are curable in 90% of patients.

Dr. Lynch served in the United States Navy during World War II in the South Pacific from 1944 to 1946 and then graduated from the University of Oklahoma at Norman in 1951. He earned an M.A. from the University of Denver in 1952, completed the course work for a Ph.D. in Human Genetics and then received his M.D. from the University of Texas Medical Branch at Galveston in 1960. He completed his medical residency at the University of Nebraska Medical Center (UNMC) in Omaha in 1964 and a 2-year fellowship in medical oncology, also at UNMC, in 1966. He joined the Creighton University faculty in 1967 after a year as an Assistant Professor of Biology and Assistant Internist at the M. D. Anderson Hospital and Tumor Institute in Houston, TX.

Dr. Lynch has published more than 400 articles and over a dozen books related to heredity and the diagnosis, prevention, counseling, and treatment of hereditary cancers. In addition to his being honored with the 1996 Bristol-Myers Squibb Award, Dr. Lynch's contributions to cancer research have been recognized by his receipt of the American Cancer Society Distinguished Service Award, the Ungerman-Lubin Lecture Prize for Outstanding Cancer Research, and Creighton University's Distinguished Research Career Award. He is a member of the American Medical Association and the American Society of Clinical Oncology. Dr. Lynch also serves on the editorial board of Anticancer Research-International Journal of Cancer Research and Treatment and on the editorial advisory boards of Critical Reviews in Oncogenesis and the Journal of Tumor Marker Oncology.